CD276 and breast carcinoma: CD276 (also known as B7-H3, Uniprot: Q5ZPR3) [24], an immune checkpoint molecule that suppresses natural killer (NK) and T cells responses [25–27], is overexpressed in >80% of breast cancers [28–30], making it an attractive target for TNBC-specific therapy.